奥沙利铂及顺铂联合长春瑞滨治疗晚期非小细胞肺癌随机对照临床研究

《奥沙利铂及顺铂联合长春瑞滨治疗晚期非小细胞肺癌随机对照临床研究》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、.临床研究-奥沙利钳及顺钳联合长春瑞滨治疗晚期非小细胞肺癌随机对照临床研究任莉朱江勾红峰耶盘何建平【摘要】背景与目的顺钳(DDP》与氏春瑞滨(NVB)联合应用是出前公认的治疗非小细胞肺癌(NSCLO的标准化疗方案之一.但顺钳所致的恶心呕吐等消化道症状严巫影响想者的生活质ffiL本研究拟观察奥沙利WKOXA)和顺铀分别与长详瑞滨联合治疗晚期NSC1.C的临床疗效和不良反应。方法168例中晚期NSC1.C想者随机进入奥沙利钳(NO)组和顺钳(NP)组。结果NO组与NP纽总有效率分别为38.6%和40.0%・1年生存率分别为33.7

2、%和31.8%,两组间差异均无统计学意义(P>0.05).两组的主要不良反应为骨競抑制、恶心呕吐及周附神经炎。NO组的白细胞减少及恶心呕吐发生率显著低于NP组(PV0.05八其周掏神经廊性的发生率明显高于NP组(PV0.001).但两组间

3、

4、

5、+IV度周围神经炎发生率善异无统计学意义(P>0.05).两组间肝肾功损害、脱发和静脉炎发生率差异无统计学意义。结论两种方案在晚期NSCLC治疗中疗效和1年生存净相近•但NO组除周围神经毒性发生率较高外，其它毒性较NP组更轻•患者更易耐受。【关键词】奥沙利钳噸钳长春瑞滨化疗非小细胞肺癌【

6、中图分类号】R734.2；R730.53Arandomizedclinicaltrialofchemotherapycombinedwithoxaliplatinandcisplatinplusnavelbineinthetreatmentofadvancednon-smallcelllungcancerRENLi,ZHUJiangGOUHongfeng,YANXi,HEJian・ping.DepartmentofMedicalOncology»CancerCenter,WestChinaHospitaltSichuanUn

7、iversityCheng-du^Sichuan610041♦P.R.ChinaCorrespondingauthor:RENLi(Abstract]BackgroundandobjectiveCisplatinplusnavelbine(NO)isastandardcombinationchemotherapyregimenfornonsmallcelllungcancer(NSCLC)tbutseveretoxicitiesduetocisplatinofteninfluencethequalityoflifeinthe

8、patients^suchasnauseaandvomiting.TheaimsofthisstudyaretoevaluatetheefficacyandtoxicityofcombinedchemotherapyofoxaliplatinandcisplatinplusnavelbineintreatmentofadvancedNSCLC・MethodsAtotalof168patientswererandomlydividedintoNOgroup(n=83)andNPgroup(n—85).ResultsTheove

9、rallresponseratewas3&6%inNOgroupand40.0%inNPgrouprespectively.1-yearsurvivalratewas33.7%inNOgroupand31.8%inNPgroup・Therewasnosignificantdifferenceinresponserateandsurvivalbetweenthetwogroups(P>0・05).Themajorsideeffectsweremyelosuppression>nausea/vomitingandneurotoxi

10、cityinthetwogroups・Incidencesofleukopeninandnausca/vomitingweresig・nificantlylowerinNOgroupthanthoseinNPgroup(PV0・05〉■butneurotoxicityinNOgroupwasmoreobviousthanthatinNPgroup(PV0・001).ConclusionTheefficacyand1-yearsurvivalofcombinedchemotherapyofoxaliplatinandcispl

11、atinplusnavelbinearesimilarinthetreatmentofadvaneedNSC1-C・However,thesideeffectsofoxaliplatinplusnavclbinearelowerexceptforneurotoxicity・[